Pathophysiology of atrial fibrillation and chronic kidney disease

Author(s):  
Wern Yew Ding ◽  
Dhiraj Gupta ◽  
Christopher F Wong ◽  
Gregory Y H Lip

Abstract Atrial fibrillation (AF) and chronic kidney disease (CKD) are closely related conditions with shared risk factors. The growing prevalence of both AF and CKD indicates that more patients will suffer from concurrent conditions. There are various complex interlinking mechanisms with important implications for the management of these patients. Furthermore, there is uncertainty regarding the use of oral anticoagulation (OAC) in AF and CKD that is reflected by a lack of consensus between international guidelines. Therefore, the importance of understanding the implications of co-existing AF and CKD should not be underestimated. In this review, we discuss the pathophysiology and association between AF and CKD, including the underlying mechanisms, risk of thrombo-embolic and bleeding complications, influence on stroke management, and evidence surrounding the use of OAC for stroke prevention.

Author(s):  
Pablo Gomez -Fernández ◽  
Antonio Martín Santana ◽  
Juan de Dios Arjona Barrionuevo

CHEST Journal ◽  
2009 ◽  
Vol 135 (4) ◽  
pp. 983-990 ◽  
Author(s):  
Sergio Manzano-Fernández ◽  
Francisco Marín ◽  
Francisco J. Pastor-Pérez ◽  
Cesar Caro ◽  
Francisco Cambronero ◽  
...  

2020 ◽  
Vol 33 (3) ◽  
pp. 483-495 ◽  
Author(s):  
Maura Ravera ◽  
Elisabetta Bussalino ◽  
Maria Fusaro ◽  
Luca Di Lullo ◽  
Filippo Aucella ◽  
...  

2016 ◽  
Vol 23 (19) ◽  
pp. 2055-2069 ◽  
Author(s):  
Tatjana S. Potpara ◽  
Vera Jokic ◽  
Nikolaos Dagres ◽  
Torben B. Larsen ◽  
Deirdre A. Lane ◽  
...  

ESC CardioMed ◽  
2018 ◽  
pp. 2237-2240
Author(s):  
Ken Okumura ◽  
Hirofumi Tomita

Atrial fibrillation (AF) is one of the common cardiovascular complications in patients with chronic kidney disease (CKD), and enhances synergistically the risks of stroke, systemic thromboembolism, and bleeding complications, resulting in increased mortality. One major concern in the treatment strategy for patients with AF and CKD has been a lack of robust evidence that improves quality of life and prognosis. Although a paradigm shift from warfarin to non-vitamin K antagonist oral anticoagulants has occurred in stroke prevention in AF, the role and indication of non-vitamin K antagonist oral anticoagulants remain to be established in patients with advanced CKD. Considering the fact that the prevalence of CKD in the general population increases with age, elderly people suffering from both CKD and AF will be increasingly frequent in the highly aged societies.


2013 ◽  
Vol 29 (7) ◽  
pp. S71-S78 ◽  
Author(s):  
Robert G. Hart ◽  
John W. Eikelboom ◽  
K. Scott Brimble ◽  
M. Sean McMurtry ◽  
Alistair J. Ingram

2016 ◽  
Vol 117 (3) ◽  
pp. 477-482 ◽  
Author(s):  
Shmuel Schwartzenberg ◽  
Eli I. Lev ◽  
Alexander Sagie ◽  
Asher Korzets ◽  
Ran Kornowski

Sign in / Sign up

Export Citation Format

Share Document